Research highlights from the 2018 ERS International Congress: interstitial lung diseases

Tiago M Alfaro¹, Catharina C Moor², Veronica Alfieri³, Florence Jeny^{4

5}, Michael Kreuter⁶, Marlies S Wijsenbeek², Elisabetta A Renzoni^{7

8

9}, Elena Bargagli¹⁰, Hilario Nunes^{4

5}, Paolo Spagnolo¹¹, Francesco Bonella¹², Maria Molina-Molina^{13

14

15}, Katerina Antoniou¹⁶, Venerino Poletti^{17

18}

Affiliations

¹ Unit of Respiratory Medicine A, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
² Dept of Respiratory Medicine, Erasmus Medical Center, University Hospital Rotterdam, Rotterdam, The Netherlands.
³ Respiratory Disease and Lung Function Unit, Dept of Medicine and Surgery, University of Parma, Parma, Italy.
⁴ AP-HP, Pneumology Dept, Avicenne Hospital, Centre de Référence des Maladies Pulmonaires Rares, Bobigny, France.
⁵ Paris 13 University, EA2363, Sorbonne Paris Cité, Bobigny, France.
⁶ Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Critical Care Medicine, Thoraxklinik, University of Heidelberg and Translational Lung Research Center Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany.
⁷ Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK.
⁸ NIHR Clinical Research Facility, Royal Brompton Hospital, London, UK.
⁹ Fibrosis Research Group, Inflammation Repair and Development Section, Imperial College London, London, UK.
¹⁰ Section of Respiratory Diseases and Lung Transplantation, Dept of Clinical Medicine and Neurosciences, Siena University Hospital, Siena, Italy.
¹¹ Section of Respiratory Diseases, Dept of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padua, Italy.
¹² Interstitial and Rare Lung Disease Unit, Dept of Pulmonary Medicine, University Hospital - Ruhrlandklinik, Essen, Germany.
¹³ Dept of Pneumology, Bellvitge University Hospital, Barcelona, Spain.
¹⁴ Pneumology Research Group, IDIBELL, University of Barcelona, Barcelona, Spain.
¹⁵ Research Network in Respiratory Diseases (CIBERES), ISCIII, Madrid, Spain.
¹⁶ Dept of Thoracic Medicine, Heraklion University Hospital, Medical School, University of Crete, Heraklion, Greece.
¹⁷ Dept of Diseases of the Thorax, Ospedale GB Morgagni, Forlì, Italy.
¹⁸ Dept of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark.

PMID: 30792985
PMCID: PMC6378342
DOI: 10.1183/23120541.00215-2018

Review

Research highlights from the 2018 ERS International Congress: interstitial lung diseases

Tiago M Alfaro et al. ERJ Open Res. 2019.

. 2019 Feb 18;5(1):00215-2018.

doi: 10.1183/23120541.00215-2018. eCollection 2019 Feb.

Authors

Affiliations

¹ Unit of Respiratory Medicine A, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
² Dept of Respiratory Medicine, Erasmus Medical Center, University Hospital Rotterdam, Rotterdam, The Netherlands.
³ Respiratory Disease and Lung Function Unit, Dept of Medicine and Surgery, University of Parma, Parma, Italy.
⁴ AP-HP, Pneumology Dept, Avicenne Hospital, Centre de Référence des Maladies Pulmonaires Rares, Bobigny, France.
⁵ Paris 13 University, EA2363, Sorbonne Paris Cité, Bobigny, France.
⁶ Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Critical Care Medicine, Thoraxklinik, University of Heidelberg and Translational Lung Research Center Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany.
⁷ Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK.
⁸ NIHR Clinical Research Facility, Royal Brompton Hospital, London, UK.
⁹ Fibrosis Research Group, Inflammation Repair and Development Section, Imperial College London, London, UK.
¹⁰ Section of Respiratory Diseases and Lung Transplantation, Dept of Clinical Medicine and Neurosciences, Siena University Hospital, Siena, Italy.
¹¹ Section of Respiratory Diseases, Dept of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padua, Italy.
¹² Interstitial and Rare Lung Disease Unit, Dept of Pulmonary Medicine, University Hospital - Ruhrlandklinik, Essen, Germany.
¹³ Dept of Pneumology, Bellvitge University Hospital, Barcelona, Spain.
¹⁴ Pneumology Research Group, IDIBELL, University of Barcelona, Barcelona, Spain.
¹⁵ Research Network in Respiratory Diseases (CIBERES), ISCIII, Madrid, Spain.
¹⁶ Dept of Thoracic Medicine, Heraklion University Hospital, Medical School, University of Crete, Heraklion, Greece.
¹⁷ Dept of Diseases of the Thorax, Ospedale GB Morgagni, Forlì, Italy.
¹⁸ Dept of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark.

PMID: 30792985
PMCID: PMC6378342
DOI: 10.1183/23120541.00215-2018

Abstract

This article reviews a selection of the scientific presentations on interstitial lung disease (ILD)/diffuse parenchymal lung disease (DPLD) that were made at the 2018 European Respiratory Society (ERS) International Congress in Paris. A number of advances in the epidemiology, pathogenesis, diagnosis and treatment of these disorders were presented and discussed by clinicians and researchers. The research topics span over all four groups of ERS Assembly 12: Interstitial Lung Diseases (Group 12.01: Idiopathic interstitial pneumonias; Group 12.02: ILD/DPLD of known origin; Group 12.03: Sarcoidosis and other granulomatous ILD/DPLD; Group 12.04: Rare ILD/DPLD).

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: T.M. Alfaro reports receiving travel support from Boehringer Ingelheim, Novartis, Astra, Menarini, Mundipharma, Zambon and Roche, and grants from Bayer, outside the submitted work. Conflict of interest: C.C. Moor has nothing to disclose. Conflict of interest: V. Alfieri has nothing to disclose. Conflict of interest: F. Jeny has nothing to disclose. Conflict of interest: M. Kreuter has nothing to disclose. Conflict of interest: M.S. Wijsenbeek reports grants and other support from Boehringer Ingelheim and Hoffman la Roche, and other support from Galapagos, outside the submitted work. Conflict of interest: E.A. Renzoni reports lecture and advisory board fees from Roche and Boehringer Ingelheim, and lecture fees from Mundipharma, outside the submitted work. Conflict of interest: E. Bargagli has nothing to disclose. Conflict of interest: H. Nunes reports consultancy and research support fees from Roche/Genentech and Boehringer Ingelheim, and grants and personal fees as a clinical trial investigator from Sanofi and Gilead. Conflict of interest: P. Spagnolo reports personal fees and nonfinancial support from Roche, Boehringer Ingelheim and Zambon, personal fees from PPM Services, Galapagos and Santhera Pharmaceuticals, outside the submitted work. Conflict of interest: F. Bonella reports personal fees and nonfinancial support from Roche Pharma, Boehringer Ingelheim and Fujrebio, outside the submitted work. Conflict of interest: M. Molina-Molina reports grants from Roche, Boehringer Ingelheim and grants from Esteve-Teijin Healthcare, and personal fees for specialised medical training from Chiesi, outside the submitted work. Conflict of interest: K. Antoniou has nothing to disclose. Conflict of interest: V. Poletti has nothing to disclose.

References

1. Dymek B, Sklepkiewicz P, Mlacki M, et al. CHIT1 is a novel therapeutic target in idiopathic pulmonary fibrosis (IPF): anti-fibrotic efficacy of OATD-01, a potent and selective chitinase inhibitor in the mouse model of pulmonary fibrosis. Eur Respir J 2018; 52: Suppl. 62, OA5361.
1. Lipner J, Lissy M, Dymek B, et al. Phase 1, first-in-human study of OATD-01, a dual chitinase inhibitor for the treatment of respiratory diseases. Eur Respir J 2018; 52: Suppl. 62, PA5228.
1. Wolffs K, Mansfield B, Scofield S, et al. Calcium-sensing receptor as a therapeutic target for pulmonary fibrosis. Eur Respir J 2018; 52: Suppl. 62, OA5365.
1. Montgomery A, Otto K, Khoo J, et al. Late Breaking Abstract – Phase 1 dose escalation study of aerosolized pirfenidone in normal healthy volunteers (NHV), smokers, and IPF patients. Eur Respir J 2018; 52: Suppl. 62, OA266.
1. Lee J, La J, Aziz S, et al. Molecular markers of telomere dysfunction and senescence are common findings in the usual interstitial pneumonia pattern of lung fibrosis. Eur Respir J 2018; 52: Suppl. 62, OA5363. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Research highlights from the 2018 ERS International Congress: interstitial lung diseases

Affiliations

Research highlights from the 2018 ERS International Congress: interstitial lung diseases

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources